JP2013522292A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013522292A5 JP2013522292A5 JP2013500056A JP2013500056A JP2013522292A5 JP 2013522292 A5 JP2013522292 A5 JP 2013522292A5 JP 2013500056 A JP2013500056 A JP 2013500056A JP 2013500056 A JP2013500056 A JP 2013500056A JP 2013522292 A5 JP2013522292 A5 JP 2013522292A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- heterocyclyl
- acceptable salt
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 27
- 150000001875 compounds Chemical class 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 15
- 239000011780 sodium chloride Substances 0.000 claims 15
- -1 2 - piperazinyl Chemical group 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- 125000004385 trihaloalkyl group Chemical group 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000006682 monohaloalkyl group Chemical group 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000004982 dihaloalkyl group Chemical group 0.000 claims 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 206010066476 Haematological malignancy Diseases 0.000 claims 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N Imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 2
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010025650 Malignant melanoma Diseases 0.000 claims 2
- 206010025310 Other lymphomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 201000006934 chronic myeloid leukemia Diseases 0.000 claims 2
- 229960002411 imatinib Drugs 0.000 claims 2
- 201000009251 multiple myeloma Diseases 0.000 claims 2
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 claims 1
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000009956 Adenocarcinoma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010008943 Chronic leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 1
- 206010020243 Hodgkin's disease Diseases 0.000 claims 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims 1
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims 1
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims 1
- 208000003747 Lymphoid Leukemia Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N Nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 1
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 210000003491 Skin Anatomy 0.000 claims 1
- 206010046766 Uterine cancer Diseases 0.000 claims 1
- 230000001154 acute Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 201000002797 childhood leukemia Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 201000006439 lymphocytic leukemia Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 229960001346 nilotinib Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 0 *c1n[n]c2c1ccc(*c1ccccc1)c2 Chemical compound *c1n[n]c2c1ccc(*c1ccccc1)c2 0.000 description 1
Claims (20)
- 式I:
Xは、NR、Sまたは結合であり;
ここでRは、HおよびC1〜6アルキルから選択され;
R1aおよびR1bは任意に、独立して、H、C1〜6アルキル、C(O)−C3〜6シクロアルキルおよびC(O)−フェニルから選択され;
ここで該C1〜6アルキル、C(O)−C3〜6シクロアルキルおよびC(O)−フェニルは、独立して、ヘテロシクリルまたはヘテロシクリル−C1〜6アルキルで1回またはそれより多くの回数置換されていてもよく;
RAは、H、C1〜6アルキル、C1〜6アルコキシおよびQR5から選択され(ただしRAのうち少なくとも1つは、QR5である);
ここでQは、−C(O)−、−C(O)N(H)−、−NHC(O)−、および、−N(H)C(O)N(H)−から選択され;および、
R5は、C1〜6アルキル、C3〜6シクロアルキル、C3〜6シクロへテロアルケニル、C1〜6アルキルオキシ、ヘテロシクリルまたはフェニル環から選択され;
ここで該C1〜6アルキル、C3〜6シクロアルキル、C3〜6シクロへテロアルキル、C1〜6アルキルオキシ、ヘテロシクリルまたはフェニル環は任意に、独立して、C1〜6アルキル、C2〜6アルケニル、C1〜6ヘテロアルキル、C1〜6モノハロアルキル、C1〜6ジハロアルキル、C1〜6トリハロアルキル、ヘテロシクリル、ヘテロアリール、ヘテロアリール−C1〜6アルキル、または、C1〜6アルキル−ヘテロシクリル−C1〜6アルキルで1回またはそれより多くの回数置換されていてもよく;および、
nは、1〜5から選択される]
で示される化合物、または、それらの医薬的に許容される塩。 - Qは、−C(O)N(H)−、−NHC(O)−、および、−N(H)C(O)N(H)−から選択され;および、
R5はフェニル環であり、該フェニル環は任意に、独立して、C1〜6アルキル、C2〜6アルケニル、C1〜6ヘテロアルキル、C1〜6モノハロアルキル、C1〜6ジハロアルキル、C1〜6トリハロアルキル、ヘテロシクリル、ヘテロアリール、ヘテロアリール−C1〜6アルキル、または、C1〜6アルキル−ヘテロシクリル−C1〜6アルキルで1回またはそれより多くの回数置換されていてもよい、
請求項1に記載の化合物、または、それらの医薬的に許容される塩。 - 式II:
R1aおよびR1bは任意に、独立して、H、C1〜6アルキル、C(O)−C3〜6シクロアルキルおよびC(O)−フェニルから選択され;
ここで該フェニルは、独立して、H、ヘテロシクリルまたはヘテロシクリル−C1〜6アルキルで1回またはそれより多くの回数置換されていてもよく;
R2は、HおよびC1〜6アルキルから選択され;および、
R3およびR4は任意に、独立して、HおよびQR5から選択され(ただし、R3およびR4の一方のみがHである);
ここでQは、−C(O)N(H)−、−NHC(O)−、および、−N(H)C(O)N(H)−から選択され;
R5はフェニル環であり、該フェニル環は任意に、独立して、H、C1〜6アルキル、C1〜6ヘテロアルキル、C1〜6モノハロアルキル、C1〜6ジハロアルキル、C1〜6トリハロアルキル、ヘテロシクリル、ヘテロアリール、ヘテロアリール−C1〜6アルキル、または、C1〜6アルキル−ヘテロシクリル−C1〜6アルキルで1回またはそれより多くの回数置換されていてもよく;
ここでヘテロシクリル部分は置換されていてもよいし、または置換されていなくてもよい]
で示される、請求項1に記載の化合物、または、それらの医薬的に許容される塩。 - R 1a は、H、CH3、C(O)−シクロプロピル、C(O)Ph、または、C(O)Ph−ピペラジニル−CH3であり;
R1bは、Hであり;
R2は、HまたはCH3であり;
R3は、HまたはC(O)N(H)−R5であり;
R4は、HまたはQR5であり;
ここでR5は:
ここでR6は、Hであり;
R7は、H、CF3、および、イミダゾリル−CH3から選択され;
R8は、H、−CH2−ピペラジニル−CH3、および、−CH2−ピペラジニル−CH2CH3から選択され;および、
R9は、H、CF3、および、イミダゾリル−CH3から選択される、請求項5に記載の化合物、または、その医薬的に許容される塩。 - Xは、NRである、請求項5に記載の化合物、または、その医薬的に許容される塩。
- Xは、結合である、請求項5に記載の化合物、または、その医薬的に許容される塩。
- Xは、結合である、請求項6に記載の化合物、または、その医薬的に許容される塩。
- 式Iで示される化合物は、表Aに列挙された化合物から選択される、請求項1に記載の化合物、または、その医薬的に許容される塩。
- 請求項1〜14のいずれかに記載の化合物またはその医薬的に許容される塩を含む、癌の治療剤。
- 前記癌は、腺癌、多発性骨髄腫、慢性骨髄性白血病、膵臓癌、非小細胞肺癌、肺癌、乳癌、結腸癌、卵巣癌、子宮頚癌、子宮癌、前立腺癌、悪性黒色腫、非黒色腫皮膚癌、消化管間質腫瘍、血液系腫瘍、血液学的悪性腫瘍、小児白血病、小児リンパ腫、多発性骨髄腫、ホジキン病、リンパ球性リンパ腫、皮膚リンパ腫、急性白血病、慢性白血病、急性リンパ性白血病、急性骨髄性白血病、慢性骨髄性白血病、形質細胞性腫瘍、リンパ性腫瘍、および、AIDS関連の癌からなる群より選択される、請求項15に記載の治療剤。
- 前記癌は、イマチニブでの治療に対して耐性を有する、請求項15に記載の治療剤。
- さらに、医薬的に有効な量の追加の抗癌剤を組み合わせてなる、請求項15に記載の治療剤。
- 前記その他の抗癌剤は、イマチニブ、または、ニロチニブである、請求項18に記載の治療剤。
- 請求項1に記載の化合物またはその医薬的に許容される塩、および医薬的に許容されるキャリアーを含む医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31440210P | 2010-03-16 | 2010-03-16 | |
US61/314,402 | 2010-03-16 | ||
PCT/US2011/025423 WO2011115725A2 (en) | 2010-03-16 | 2011-02-18 | Indazole compounds and their uses |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013522292A JP2013522292A (ja) | 2013-06-13 |
JP2013522292A5 true JP2013522292A5 (ja) | 2014-04-03 |
Family
ID=43971357
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013500056A Pending JP2013522292A (ja) | 2010-03-16 | 2011-02-18 | インダゾール化合物およびそれらの使用 |
Country Status (11)
Country | Link |
---|---|
US (1) | US8987275B2 (ja) |
EP (1) | EP2547661A2 (ja) |
JP (1) | JP2013522292A (ja) |
KR (1) | KR20130006664A (ja) |
CN (1) | CN103080093A (ja) |
AU (1) | AU2011227643A1 (ja) |
BR (1) | BR112012023021A2 (ja) |
CA (1) | CA2791613A1 (ja) |
EA (1) | EA201290919A1 (ja) |
MX (1) | MX2012010617A (ja) |
WO (1) | WO2011115725A2 (ja) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2440559B1 (en) | 2009-05-05 | 2018-01-10 | Dana-Farber Cancer Institute, Inc. | Egfr inhibitors and methods of treating disorders |
US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
WO2012127030A1 (en) * | 2011-03-23 | 2012-09-27 | Proteosys Ag | Arylpiperazines as neuroprotective agents |
AU2012340200B2 (en) | 2011-11-17 | 2017-10-12 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-Terminal Kinase (JNK) |
PT3495367T (pt) | 2012-06-13 | 2020-11-12 | Incyte Holdings Corp | Compostos tricíclicos substituídos como inibidores de fgfr |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
WO2014063068A1 (en) | 2012-10-18 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
WO2014063061A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
WO2014063054A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof |
EP2914266B1 (en) * | 2012-11-01 | 2019-06-19 | University of South Carolina | Cdk8/cdk19 selective inhibitors for use in a method for treating prostate cancer |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
TWI715901B (zh) | 2013-04-19 | 2021-01-11 | 美商英塞特控股公司 | 作為fgfr抑制劑之雙環雜環 |
JP6491202B2 (ja) | 2013-10-18 | 2019-03-27 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | サイクリン依存性キナーゼ7(cdk7)の多環阻害剤 |
ES2676734T3 (es) | 2013-10-18 | 2018-07-24 | Syros Pharmaceuticals, Inc. | Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas |
WO2015164614A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
WO2015164604A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
EP3229807A4 (en) | 2014-12-11 | 2018-10-17 | President and Fellows of Harvard College | Inhibitors of cellular necrosis and related methods |
EP3233840B1 (en) | 2014-12-16 | 2018-11-21 | Eudendron S.r.l. | Heterocyclic derivatives modulating activity of certain protein kinases |
EP3236959A4 (en) | 2014-12-23 | 2018-04-25 | Dana Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
CN113004278B (zh) | 2015-02-20 | 2023-07-21 | 因赛特控股公司 | 作为fgfr抑制剂的双环杂环 |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
CA2978518C (en) | 2015-03-27 | 2023-11-21 | Nathanael S. Gray | Inhibitors of cyclin-dependent kinases |
AU2016276963C1 (en) | 2015-06-12 | 2021-08-05 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
CA2996978A1 (en) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
KR20170085619A (ko) * | 2016-01-14 | 2017-07-25 | 연세대학교 산학협력단 | Alk 저해제에 대한 내성을 획득한 eml4-alk 양성 비소세포폐암의 치료를 위한 스타틴계 약물의 용도 |
EP3512837B1 (en) * | 2016-09-15 | 2020-07-22 | Boehringer Ingelheim International GmbH | Pyridine and pyrazine compounds as inhibitors of ripk2 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
WO2019213544A2 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
CR20200591A (es) | 2018-05-04 | 2021-03-31 | Incyte Corp | Sales de un inhibidor de fgfr |
CN111138426B (zh) * | 2018-11-02 | 2023-03-10 | 安徽中科拓苒药物科学研究有限公司 | 吲唑类激酶抑制剂及其用途 |
WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
WO2021046515A1 (en) | 2019-09-06 | 2021-03-11 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
US11753381B2 (en) | 2019-09-27 | 2023-09-12 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase I for the treatment of disease |
KR20220079593A (ko) * | 2019-10-03 | 2022-06-13 | 브리스톨-마이어스 스큅 컴퍼니 | 키나제 억제제로서의 인다졸 카르복스아미드 |
TW202128685A (zh) | 2019-10-14 | 2021-08-01 | 美商英塞特公司 | 作為fgfr抑制劑之雙環雜環 |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
CN114981248A (zh) | 2019-11-26 | 2022-08-30 | 德州大学系统董事会 | 用于治疗疾病的受体相互作用蛋白激酶i的抑制剂 |
EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
CA3162010A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
HU204253B (en) | 1982-11-22 | 1991-12-30 | Sandoz Ag | Process for producing mevalonolactone analogues and derivatives and pharmaceutical compositions containing them |
US4885314A (en) | 1987-06-29 | 1989-12-05 | Merck & Co., Inc. | Novel HMG-CoA reductase inhibitors |
US4782084A (en) | 1987-06-29 | 1988-11-01 | Merck & Co., Inc. | HMG-COA reductase inhibitors |
US5420245A (en) | 1990-04-18 | 1995-05-30 | Board Of Regents, The University Of Texas | Tetrapeptide-based inhibitors of farnesyl transferase |
US5747469A (en) | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
EP0604181A1 (en) | 1992-12-21 | 1994-06-29 | Eli Lilly And Company | Antitumor compositions and method of treatment |
WO1994019357A1 (en) | 1993-02-23 | 1994-09-01 | Merrell Dow Pharmaceuticals Inc. | Farnesyl:protein transferase inhibitors as anticancer agents |
CA2118985A1 (en) | 1993-04-02 | 1994-10-03 | Dinesh V. Patel | Heterocyclic inhibitors of farnesyl protein transferase |
AU6909194A (en) | 1993-05-14 | 1994-12-12 | Board Of Regents, The University Of Texas System | Preparation of n-cyanodithioimino-carbonates and 3-mercapto-5-amino-1h-1,2,4-triazole |
US5602098A (en) | 1993-05-18 | 1997-02-11 | University Of Pittsburgh | Inhibition of farnesyltransferase |
EP0670314A4 (en) | 1993-09-22 | 1996-04-10 | Kyowa Hakko Kogyo Kk | FARNESYL-TRANSFERASE INHIBITOR. |
US5721236A (en) | 1993-10-15 | 1998-02-24 | Schering Corporation | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US5661152A (en) | 1993-10-15 | 1997-08-26 | Schering Corporation | Tricyclic sulfonamide compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
IL111235A (en) | 1993-10-15 | 2001-03-19 | Schering Plough Corp | Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them |
HUT76057A (en) | 1993-10-15 | 1997-06-30 | Schering Corp | Tricyclic sulfonamide compounds, pharmaceutical compositions containing them, which are useful for inhibition of g-protein function and for treatment of proliferative diseases and process for producing them |
US5719148A (en) | 1993-10-15 | 1998-02-17 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
JP2875393B2 (ja) | 1993-10-15 | 1999-03-31 | シェーリング コーポレイション | G−タンパク質機能の阻害および増殖性疾患の治療に有用な三環式カルバメート化合物 |
DE69427127T2 (de) | 1993-10-25 | 2001-10-04 | Parke Davis & Co | Substituierte tetra- und pentapeptid hemmstoffe der farnesyl protein transferase |
US5783593A (en) | 1993-11-04 | 1998-07-21 | Abbott Laboratories | Inhibitors of squalene synthetase and protein farnesyltransferase |
ATE177420T1 (de) | 1993-11-04 | 1999-03-15 | Abbott Lab | Cyclobutan-derivate als inhibitoren der squalen- synthetase und der protein-farnesyltransferase |
HUT75308A (en) | 1993-11-05 | 1997-05-28 | Warner Lambert Co | Substituted di- and tripeptide inhibitors of protein:farnesyl transferase |
US5484799A (en) | 1993-12-09 | 1996-01-16 | Abbott Laboratories | Antifungal dorrigocin derivatives |
WO1995024612A1 (de) | 1994-03-07 | 1995-09-14 | International Business Machines Corporation | Verfahren und vorrichtung zur schnellen interpolation von zwischenwerten aus periodischen phasenverschobenen signalen und zur erkennung von defekten in einem drehkörper |
HUT77406A (hu) | 1994-03-15 | 1998-04-28 | Eisai Co., Ltd., | 1-(4-Amino-5-tio-pent-2-en)-il oldalláncot tartalmazó peptidomimetikumok és az ezeket tartalmazó gyógyszerkészítmények |
US6312699B1 (en) | 1994-03-28 | 2001-11-06 | Uab Research Foundation | Ligands added to adenovirus fiber |
HUT72440A (en) | 1994-03-31 | 1996-04-29 | Bristol Myers Squibb Co | Imidazole-containing inhibitors of farnesyl protein transferase and pharmaceutical compositions containing them |
US5523430A (en) | 1994-04-14 | 1996-06-04 | Bristol-Myers Squibb Company | Protein farnesyl transferase inhibitors |
US5510510A (en) | 1994-05-10 | 1996-04-23 | Bristol-Meyers Squibb Company | Inhibitors of farnesyl protein transferase |
US5563255A (en) | 1994-05-31 | 1996-10-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
CA2192389A1 (fr) | 1994-06-10 | 1995-12-21 | Bernard Baudoin | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
US5571792A (en) | 1994-06-30 | 1996-11-05 | Warner-Lambert Company | Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase |
WO1996005529A1 (en) | 1994-08-09 | 1996-02-22 | Micron Optics, Inc. | Temperature compensated fiber fabry-perot filters |
AU3192395A (en) | 1994-08-11 | 1996-03-07 | Banyu Pharmaceutical Co., Ltd. | Substituted amide derivative |
CA2155448A1 (en) | 1994-08-11 | 1996-02-12 | Katerina Leftheris | Inhibitors of farnesyl protein transferase |
EP0805154A1 (en) | 1994-08-12 | 1997-11-05 | Banyu Pharmaceutical Co., Ltd. | N,n-disubstituted amic acid derivative |
DE4429506B4 (de) | 1994-08-19 | 2007-09-13 | Degussa Gmbh | Verfahren zur Extraktion natürlicher Carotinoid-Farbstoffe |
DE4429653C2 (de) | 1994-08-20 | 1997-04-03 | Anton Dr More | Konverter und Verfahren zum Frischen von Metallschmelzen insbesondere von Roheisen zu Stahl |
DE69507284T2 (de) | 1994-11-22 | 1999-07-01 | Philips Electronics Nv | Halbleiter mit einem träger auf dem ein substrat mit einem halbleiter-element mittels einer klebeschicht und ein leiterbahn-muster befestigt sind |
WO1996017861A1 (en) | 1994-12-09 | 1996-06-13 | Warner-Lambert Company | Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase |
AU703440B2 (en) | 1995-01-09 | 1999-03-25 | Magla International Ltd. | Wear resistant image printing on latex surfaces |
WO1996021456A1 (en) | 1995-01-12 | 1996-07-18 | University Of Pittsburgh | Inhibitors of prenyl transferases |
FR2729390A1 (fr) | 1995-01-18 | 1996-07-19 | Rhone Poulenc Rorer Sa | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
FR2730491B1 (fr) | 1995-02-09 | 1997-03-14 | Rhone Poulenc Rorer Sa | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
FR2730492B1 (fr) | 1995-02-09 | 1997-03-14 | Rhone Poulenc Rorer Sa | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
US5684013A (en) | 1995-03-24 | 1997-11-04 | Schering Corporation | Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
US5700806A (en) | 1995-03-24 | 1997-12-23 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
IL117580A0 (en) | 1995-03-29 | 1996-07-23 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them |
US5891872A (en) | 1995-04-07 | 1999-04-06 | Schering Corporation | Tricyclic compounds |
MX9707561A (es) | 1995-04-07 | 1997-12-31 | Schering Corp | Compuestos de carbonil piperazinilo y piperidinilo. |
IL117798A (en) | 1995-04-07 | 2001-11-25 | Schering Plough Corp | Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them |
US5712280A (en) | 1995-04-07 | 1998-01-27 | Schering Corporation | Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US5831115A (en) | 1995-04-21 | 1998-11-03 | Abbott Laboratories | Inhibitors of squalene synthase and protein farnesyltransferase |
IL118101A0 (en) | 1995-05-03 | 1996-09-12 | Abbott Lab | Inhibitors of farnesyltransferase |
AU6034296A (en) | 1995-06-16 | 1997-01-15 | Warner-Lambert Company | Tricyclic inhibitors of protein farnesyltransferase |
FR2736641B1 (fr) | 1995-07-10 | 1997-08-22 | Rhone Poulenc Rorer Sa | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
AT402617B (de) | 1995-07-11 | 1997-07-25 | Datacon Schweitzer & Zeindl Gm | Anlage zum automatisierten, hermetischen anlage zum automatisierten, hermetischen verschliessen von gehäusen verschliessen von gehäusen |
FR2736638B1 (fr) | 1995-07-12 | 1997-08-22 | Rhone Poulenc Rorer Sa | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
CH690163A5 (fr) | 1995-07-28 | 2000-05-31 | Symphar Sa | Dérivés gem-diphosphonates substitués utiles en tant qu'agents anti-cancers. |
ES2196186T3 (es) | 1995-11-06 | 2003-12-16 | Univ Pittsburgh | Inhibidores de protein-isoprenil-transferasas. |
AU704139B2 (en) | 1995-11-22 | 1999-04-15 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
DE69620445T2 (de) | 1995-12-08 | 2002-12-12 | Janssen Pharmaceutica Nv | (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren |
SK86198A3 (en) | 1995-12-22 | 1999-02-11 | Schering Corp | Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases |
AU1529997A (en) | 1996-01-16 | 1997-08-11 | Warner-Lambert Company | Substituted histidine inhibitors of protein farnesyltransferase |
US6673927B2 (en) | 1996-02-16 | 2004-01-06 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | Farnesyl transferase inhibitors |
WO1997038665A2 (en) | 1996-04-03 | 1997-10-23 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
CZ376498A3 (cs) | 1996-05-22 | 1999-02-17 | Warner-Lambert Company | Inhibitory proteinové farnesyl fransferázy |
EP0918771A4 (en) | 1996-07-15 | 2001-02-07 | Bristol Myers Squibb Co | THIADIOXOBENZODIAZEPINES FOR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS |
EP1003374A1 (en) | 1996-12-30 | 2000-05-31 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
JP2001507699A (ja) | 1996-12-30 | 2001-06-12 | メルク エンド カンパニー インコーポレーテッド | ファルネシル蛋白トランスフェラーゼ阻害薬 |
IL144578A0 (en) | 1999-01-29 | 2002-05-23 | Imclone Systems Inc | Antibodies specific to kdr and uses thereof |
GB9904387D0 (en) | 1999-02-25 | 1999-04-21 | Pharmacia & Upjohn Spa | Antitumour synergistic composition |
AU4972900A (en) | 1999-04-08 | 2000-11-14 | Arch Development Corporation | Use of anti-vegf antibody to enhance radiation in cancer therapy |
PE20010306A1 (es) * | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
WO2003051847A1 (en) * | 2001-12-19 | 2003-06-26 | Smithkline Beecham P.L.C. | (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors |
FR2836915B1 (fr) * | 2002-03-11 | 2008-01-11 | Aventis Pharma Sa | Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
CA2486101C (en) | 2002-05-17 | 2009-07-07 | Pharmacia Italia S.P.A. | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
GB0217757D0 (en) * | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Novel compounds |
US20040235892A1 (en) * | 2003-05-22 | 2004-11-25 | Yujia Dai | Indazole and benzisoxazole kinase inhibitors |
SI1638941T1 (sl) * | 2003-05-22 | 2010-11-30 | Abbott Lab | Inhibitorji indazol benzizoksazol in benzizotiazol kinaze |
SE0301906D0 (sv) * | 2003-06-26 | 2003-06-26 | Astrazeneca Ab | New compounds |
FR2871158A1 (fr) * | 2004-06-04 | 2005-12-09 | Aventis Pharma Sa | Indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
DE102004028862A1 (de) * | 2004-06-15 | 2005-12-29 | Merck Patent Gmbh | 3-Aminoindazole |
US7632854B2 (en) * | 2004-11-17 | 2009-12-15 | Pfizer Italia S.R.L. | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
WO2007024680A1 (en) * | 2005-08-22 | 2007-03-01 | Amgen Inc. | Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators |
EP2120932B1 (en) * | 2006-12-20 | 2014-07-09 | Nerviano Medical Sciences S.r.l. | Indazole derivatives as kinase inhibitors for the treatment of cancer |
WO2009028655A1 (ja) * | 2007-08-30 | 2009-03-05 | Takeda Pharmaceutical Company Limited | 複素環化合物およびその用途 |
US20100197688A1 (en) * | 2008-05-29 | 2010-08-05 | Nantermet Philippe G | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
-
2011
- 2011-02-18 CA CA2791613A patent/CA2791613A1/en not_active Abandoned
- 2011-02-18 MX MX2012010617A patent/MX2012010617A/es not_active Application Discontinuation
- 2011-02-18 JP JP2013500056A patent/JP2013522292A/ja active Pending
- 2011-02-18 AU AU2011227643A patent/AU2011227643A1/en not_active Abandoned
- 2011-02-18 KR KR1020127027019A patent/KR20130006664A/ko not_active Application Discontinuation
- 2011-02-18 BR BR112012023021A patent/BR112012023021A2/pt not_active IP Right Cessation
- 2011-02-18 CN CN2011800243883A patent/CN103080093A/zh active Pending
- 2011-02-18 WO PCT/US2011/025423 patent/WO2011115725A2/en active Application Filing
- 2011-02-18 EP EP11713102A patent/EP2547661A2/en not_active Ceased
- 2011-02-18 EA EA201290919A patent/EA201290919A1/ru unknown
- 2011-02-18 US US13/583,974 patent/US8987275B2/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2013522292A5 (ja) | ||
JP2008525530A5 (ja) | ||
JP2019535746A5 (ja) | ||
JP2019535744A5 (ja) | ||
JP2012153722A5 (ja) | ||
JP2019514863A5 (ja) | ||
JP2015517574A5 (ja) | ||
JP2020515574A5 (ja) | ||
JP2014520898A5 (ja) | ||
JP2009503110A5 (ja) | ||
JP2010523670A5 (ja) | ||
JP2016503799A5 (ja) | ||
JP2018510191A5 (ja) | ||
JP2011511095A5 (ja) | ||
JP2016500082A5 (ja) | ||
JP2013502441A5 (ja) | ||
JP2018516917A5 (ja) | ||
JP2014508811A5 (ja) | ||
JP2016513660A5 (ja) | ||
RU2012151012A (ru) | Циклопропиловые дикарбоксамиды и аналоги, обладающие противораковым и антипролиферативным действием | |
JP2012504628A5 (ja) | ||
JP2016503414A5 (ja) | ||
JP2010539095A5 (ja) | ||
JP2008535903A5 (ja) | ||
RU2014115847A (ru) | Пирролопиримидиновые соединения для лечения злокачественной опухоли |